Xeris Biopharma Holdings, Inc. (XERS) research

Xeris Biopharma Holdings, Inc.
ShareXLinkedInReddit
Sector
Pharmaceuticals
Last price
$8.80
As of

Xeris Biopharma Holdings, Inc. (XERS): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-09.

As of . Source: SEC EDGAR filings for XERS. Method and limitations.

SHARE THIS CARD

Share the XERS intelligence card

A branded snapshot of XERS: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion XERS intelligence card preview
Post to X
LIVE TERMINAL

See XERS live in the terminal

Track XERS's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live XERS terminal, free

Active signals for XERS

FREE, NO ACCOUNT

Every signal on XERS, as it fires

You are seeing 5 of 22 signals recorded on XERS since 2026-05-26.

The five above all landed on 2026-09-06. The other 17 were recorded on 3 other days. 18 of the 22 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in XERS (2026Q2)

Manager / securityMarket value% portfolioQoQ
D. E. Shaw & Co., Inc.CUSIP 98422E103 · 2026Q2$61.8M0.03%,
TWO SIGMA INVESTMENTS, LPCUSIP 98422E103 · 2026Q2$14.9M0.01%,
CITADEL ADVISORS LLCCUSIP 98422E103 · 2026Q2$5.3M0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP 98422E103 · 2026Q2$1M0.00%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 98422E103 · 2026Q2$533K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, XERS

XERS against its peers

XERS's operating margin of 8.5% ranks in the 50th percentile of 18 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.

MetricXERSPeer medianPercentilen
Revenue FY292M USD585M USD3620
Gross marginn/a53.3%n/a7
Operating margin8.5%7.6%5018
Net margin0.2%1.0%4819
Return on equity4.0%-19.3%6621
P / En/a14.6xn/a10

Peers (25): OMER, INVA, ANIP, PAHC, NUVB, TRVI, BHC, ANRO, OCUL, NKTR, ALMS, SUPN, AMPH, HRMY, GPCR, PCRX, ESPR, ACRS, COLL, OGN, AMLX, TARS, AVIR, LQDA, AMRX. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (XERS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more XERS signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to XERSand get the insider, 13F, options, and confluence read in one view.

Open the live XERS terminal, free